ESMO 2024 – Scorpion joins Relay in the alpha club
What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.
What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.
The fortunes of RLY-2608 reverse, and a pivotal study will follow.
Several companies have followed Pfizer into CDK2 inhibitor development, but the jury is out on this field’s promise.
The company’s FGFR2 inhibitor shows potential beyond cholangiocarcinoma, but the markets aren’t buying it.